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The aim of present study was to formulate and evaluate a self-microemulsifying drug
delivery systems (SMEDDS) containing lovastatin and to further explore the ability of
porous Neusilin® US2 tablet as a solid carrier for SMEDDS. SMEDDS formulations of varying
proportions of peceol, cremophor RH 40 and transcutol-P were selected and subjected to in-
vitro evaluation, including dispersibility studies, droplet size, zeta potential measurement
and release studies. The results indicated that the drug release profile of lovastatin from
SMEDDS formulations was statistically significantly higher (p-value < 0.05) than the plain
lovastatin powder. Thermodynamic stability studies also confirmed the stability of the
prepared SMEDDS formulations. The optimized formulation, which consists of 12% of
peceol, 44% of cremophor RH 40, and 44% of transcutol-P was loaded into directly com-
pressed liquid loadable tablet of Neusilin® US2 by simple adsorption method. In order to
determine the ability of Neusilin® US2 as a suitable carrier pharmacodynamics study were
also carried out in healthy diet induced hyperlipidemic rabbits. Animals were administered
with both liquid SMEDDS and solid SMEDDS as well. From the results obtained, Neusilin®
was found to be a suitable carrier for SMEDDS and was equally effective in reducing the
elevated lipid profile. In conclusion, liquid loadable tablet (LLT) is predicted to be a
promising technique to deliver a liquid formulation in solid state.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.aceutical Technology, School of Pharmacy, Taylors University, Selangor, Malaysia. Tel.: þ60
(M.J. Qureshi).
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ered are lipophilic and exhibits poor water solubility which
results in low bioavailability, intra and inter subject variation
and lack of dose proportionality [1]. Limited water solubility
posses a challenge in developing optimum oral solid dosage
form in terms of formulation design, bioavailability and mar-
keting of new pharmaceutical products. Several formulation
strategies have been approved to overcome these challenges
either bymeansofmodifying the solubilization ormaintaining
the drug in dissolved form throughout gastric transit time
[2e4]. These strategies may include the use of surfactants,
cyclodextrins, micronization, salt formation, pH change, nano
size delivery, solid dispersions and permeation enhancers
[1,5]. In fact,most commonlyused approaches are, digestion of
the active pharmaceutical ingredient into inert lipids such as
oils and surfactant dispersions [6], self-emulsifying formula-
tions [7e9] emulsions [10] and liposomes [11,12].
SMEDDS, an emulsion based formulation is a blend of oils
and surfactants in suitable proportion that rapidly forms an
oil in water (o/w) microemulsion with moderate gastric
motility when exposed to the aqueous media present in the
g.i.t [13]. Co-surfactant and organic solvent can also be added
sometime to improve the emulsification and solubility
respectively. SMEDDS typically produce a transparent micro-
emulsion having droplet size of <50 nm [14] and are physically
and thermodynamically stable formulations. Rapid emulsion
formation helps to keep the drug in a dissolved form, how-
ever, small droplet size offers a considerably larger interfacial
surface area which further accelerate the absorption rate of
drug with limited solubility. This feature makes SMEDDS a
meaningful choice for oral delivery of lipophilic, low
bioavailable drugs having adequate lipid solubility [13,15e17].
Moreover, the lipoidal part of SMEDDS encourages the in-
testinal lymphatic uptake of drugs which further helps in
avoiding the presystemic biotransformation of drug mole-
cules. Lovastatin undergoes substantial first-pass metabolism
facilitated by CYT P450 3A4 in liver. The basic mechanism in
improving the bioavailability by SMEDDS comprises of in-
crease in themembrane fluidity due to presence of surfactants
and co-surfactant which expedite transcellular absorption
[18e22]. Surfactant and co-surfactant molecules get favorably
absorbed at the liquid interface during the process of emulsion
formation, reducing the interfacial energy of the system. This
helps spontaneous emulsification without high energy input.
Thus, well-designed SMEDDS formulation can ensure efficient
self-emulsification as well as greater solubilization capability
for the drug in the resultant dispersion [23].
Choosing the right combination of lipid (oil), surfactant,
and co-surfactant is one of the important points in
designing SMEDDS formulations. Selection of a good self-
microemulsifying formulation depends on the (1) the solubi-
lity of the drug in oil/surfactant/co-surfactant (2) emulsion
forming area as determined by phase diagram, and (3) the
globule size distribution of the developed SMEDDS [24,25].
There are various reasons or challenges in developing lipid
based systems, like so far there are no definite in-vitro evalu-
ation or characterization tests which can simulate or predictthe in-vivo performance of drug administered in lipoidal for-
mulations [26,27], second is of course liquid nature of these
formulations whichmake them failure at commercial success
because of difficulties in manufacture, handling, storage,
supply and same time retain risk of stability issues too.
Because of these reasons SMEDDS formulation can only be
supplied either bottle filled or if dose is low then it could be
supplied in liquid filled soft gelatin capsule as well. Such kind
of formulations have many restrictions, first of all oral solu-
tion are not very well accepted by the patient and second
capsule filled formulation have dose limit. Drug with higher
dose is difficult to incorporate in limited space available in soft
gelatin capsule shells. Furthermore there is a risk of leaching
and precipitation if capsules shells are not properly sealed or
manufactured [28].
To overcome these limitations of liquid SMEDDS many
different approaches like spray drying [29], melt granulation,
adsorption on solid carrier [30e32] and other techniques [33]
have been explored to transform the lipid based formulation
into solid oral dosage form. Conversion of liquid formulations
into a suitable solid dosage form is an exciting but difficult
task too. From many years soft or hard gelatin capsules are
widely being used to fill and administer the liquid dosage
form. However, these capsules are also accompanying various
formulation related problems like leaching of material, leak-
ing, sticking, physical incompatibilities with capsule shell,
slower production rate compared to tablet etc. Tablets are
apparently a better substitute to liquid filled soft gelatin
capsule to administer SMEDDS in terms of patient compliance
and physical stability. Moreover, tablet can take a higher drug
load compared to capsule formulation. The major constraint
in transformation of SMEDDS into a tablet form is availability
of an appropriate carriermoleculewhich can take up a desired
quantity of liquid formulation and at the same time can
exhibit a good tablet quality as well. Liquid formulation can
easily be converted into free flowing powder form by adsorb-
ing on suitable solid carrier particles like silicate derivatives,
dextran, carbon tubes [33] and silicon dioxide. Subsequent to
adsorption these lipid loaded solid carrier can either be filled
directly into capsule housing or can be mixed with other
excipient required for tablet compression. Although this car-
rier approach seems to be effective and easy but there are
certain constraints or limitations accompanied with this
approach such as, when a solid carrier loaded with high liquid
content is subjected to compression, adsorbed liquid compo-
nent may exudate out and problems of chipping, sticking,
variable hardness and soft tablets are likely to be present.
Second, a large quantity of solid carrier is needed to adsorb the
liquid formulation which eventually will lead to large volume
of final dosage form [34].
The present study is focused to overcome these short-
comings of tablet compression by exploring the use of Neu-
silin® US2 tablets as solid carrier followed by adsorption of
liquid SMEDDS formulation. Neusilin US2 (Fuji chemicals, JP)
is a spray dried synthetic amorphous form of magnesium
aluminometasilicate (MAMS) having large surface area and
high oil and water adsorption ability. MAMS is completely
insoluble in water but have slight solubility for acid and alkali
[35]. Lovastatin was chosen as the drug to be incorporated into
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Lovastatin is a cholesterol-lowering agent which acts by
inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase, which accelerates the translation of HMG-Co
enzyme A to mevalonate which serves as precursor to
cholesterol in the biosynthetic pathway of cholesterol. Lova-
statin is reported to have less than 5% bioavailability of an
orally administered dose due to extensive first-pass meta-
bolism [36]. It is classified as a BCS Class II, with “low solubi-
lity/high permeability” therefore, it can be anticipated that the
poor oral bioavailability of lovastatin could be due to its
limited aqueous solubilization which further poses dissolu-
tion limitations [37].
The aim of present study was to develop an appropriate
SMEDDS formulation for lovastatin to improve its bioavail-
ability and also to explore the capability of LLT made from
MAMS as a carrier to be loaded with self-microemulsifying
formulation in order to enhance the physical and chemical
stability of developed delivery system. Finally the developed
lovastatin-SMEDDS and LLT loaded with SMEDDS containing
lovastatin were evaluated for pharmacodynamics efficiency
in diet induced hyperlipidemic rabbits.Table 1 e The solubility of lovastatin in different oils,
surfactants and co-surfactants.
Category Vehicle Solubility (mg/ml)
(Mean ± SD)
Oils Labrafac Lipophile 2.4203 ± 0.4525
Labrafac PG 2.7669 ± 0.7312
Peceol 14.9968 ± 0.8611
Labrafil M1944 4.9147 ± 0.0600
Lauroglycol 90 10.7568 ± 0.6732
Olive oil 1.1643 ± 0.2690
Surfactants Span 80 3.8715 ± 0.9517
Span 20 2.9200 ± 0.6048
Labrasol 18.3488 ± 2.7113
Tween 60 9.5568 ± 1.8460
Tween 80 3.8869 ± 0.9169
Tween 40 14.4384 ± 2.1711
Tween 20 12.2464 ± 3.4773
Cremophor 24.6646 ± 3.6183
Co-Surfactants Transcutol-P 37.5440 ± 1.6478
PEG 300 8.4192 ± 1.3812
PEG 400 12.3061 ± 2.0803
PEG 600 12.8987 ± 0.28362. Material and methods
2.1. Materials
Lovastatin (Shanghai PI Chemicals Ltd (China)), Neusilin®
US2 (Fuji Chemical Japan), Crospovidone (Polyplasdone XL 10,
ISP Technologies, USA), Polyglycolysed glycerides (Capryol 90,
Capyrol PGMC, Lauroglycol 90, Labrasol, Transcutol-P, Labrafil
M 1944 CS, Labrafac PG, Labrafac Lipophile and Peceol) were
provided as gift samples by Gattefosse (France). Cremophor
RH 40 was provided as gift samples by BASF Germany. Tween
80, Tween 20, Tween 40, Tween 60, Span 80, Span 20, poly-
ethylene glycol (PEG) 300, PEG 400 and PEG 600, magnesium
stearate were purchased from SigmaeAldrich (USA), Meth-
anol of HPLC grade was purchased from J. T. Baker (USA). All
the other chemicals and reagents used were of analytical
grade.
2.2. Methods
2.2.1. Solubility studies
In order to select a best combination of oils, surfactants, and
co-surfactants for SMEDDS formulation, component which
shown a maximum solubility for lovastatin was selected. An
excess quantity of lovastatin was taken into each screw-
capped glass vials which contains 2 ml of the respected
vehicle. Vials were hermetically sealed andwarmed at 40 C in
awater bath followed by stirring on a vortexmixer to facilitate
the solubilization. Later, samples were kept at room temper-
ature for 72 h in shaker bath of 150 oscillations/min. After
reaching equilibrium, the supersaturated mixture was
centrifuged at 3000 rpm for 15 min and undissolved lovastatin
was separated by filtration thru 0.45 mmpore size filter [24,38].
The amount of solubilized lovastatin was quantified by the
HPLC analysis. The results were treated statistically using
one-way analysis of variance (ANOVA), in order to determinethe statistically significant differences among the solubility of
the vehicles in each category.
2.2.2. Pseudo-ternary phase diagram
As per the solubility data presented in Table 1 cremophor,
transcutol-P and peceol, were chosen as surfactant, co-
surfactant and the oil phase respectively. To determine the
concentration of components for the prevailing range of
SMEDDS, pseudo-ternary phase diagram was drawn using
water-titrationmethod at ambient temperature [39]. Different
surfactant/co-surfactant mixtures (Smix) were prepared by
mixing the selected surfactant and co-surfactant at three fixed
ratios (1:1, 2:1 and 3:1 w/w). The selected oil was then added to
each Smix at eight different ratios (9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7,
2:8 and 1:9 w/w). Water was incorporated to each mixture in
5% step-wise increments [40] followed by gentle swirling of
the mixture. After every water addition in dropwise manner,
the mixture was visually observed for its transparency and
turbidity. The end point of turbidity-to-transparency and
transparency-to-turbidity transitions was noted [24], and the
percentages of water, oil and Smix were calculated at this
point. Based on these percentages phase diagrams were
plotted, and the microemulsion region in each phase diagram
was identified. In order to observe the influence of drug
addition on the microemulsion forming area, phase diagrams
were also constructed with drug (lovastatin) using drug-oil
mixture as the hydrophobic component [41].
2.2.3. Preparation of SMEDDS formulation
A range of formulation was formulated using transcutol-P,
cremophor RH 40 and peceol as co-surfactant, surfactant and
oil phase respectively. Lovastatin (10 mg/ml) was added into
the oily phase in small increment with continuous stirring.
The surfactant system (Smix) was prepared separately by
mixing the selected surfactant and co-surfactant in their
determined ratios chosen from the microemulsion region of
the constructed phase diagram [42]. Oil phase containing
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continuous stirring and vortex mixing till the homogenous
mixture was formed. The resulting microemulsions were
stored for a day and inspected for any possibility of physical
instability characterized by phase separation and drug pre-
cipitation. Furthermore, in order to select an optimized
SMEDDS formulation, the effect of oil to surfactant þ co-sur-
factant (O:Smix) ratio, susceptibility of droplet size for change
in pH of the dilution medium were also taken into consider-
ation [18].
2.2.4. Thermodynamic stability study
These studies, aimed at evaluating the stability of the for-
mulations prepared, consist of two phases. Phase I is the
heating cooling cycle, where all the formulations were sub-
jected to six cycles between 4 C and 45 C, with storage at
each temperature of minimum of 48 h. After complete cycles
of alternate temperatures, formulations were centrifuged at
3500 rpm for 15 min to observe for any phase separation or
drug precipitation. Formulations which succeeded in phase I
were taken to phase II (freezeethaw cycle), where the for-
mulations were subjected to three cycles of alternate tem-
perature between 21 C and þ25 C. Samples were stored for
minimum of 48 h at each temperature [42]. Succeeding to
phase II, in order to determine the physical stability, formu-
lations were further allowed to centrifuge at a speed of
3500 rpm for 15min for possibility of phase separation or drug
precipitation. Formulations which were found to be stable
at alternate temperature cycles were selected for further
evaluation.
2.2.5. Globule (droplet) size and zeta potential analysis
1 ml of the formulation was diluted to 10 ml using distilled
water. An aliquot of the resultant emulsion was then sub-
jected to the Malvern Zetasizer for droplet size and zeta po-
tential measurement at pH 7.0 and 25 C.
2.2.6. Assessment of self-emulsification
In order to determine the efficiency of self-emulsification of
various mixtures, 1 ml of each formulation was added to
250 ml of distilled water contained in a vessel of USP appa-
ratus 2, with gentle agitation, provided by a paddle rotating
at a speed of 50 rpm. Apparatus was maintained at a tem-
perature of 37 C. Self-emulsification process was visually
monitored for the emulsification rate and for the quality of
the produced microemulsion using grading system give in
Table 4.
2.2.7. Precipitation analysis
The prepared SMEDDS were diluted with 0.1 N HCl up to 250
times. The diluted microemulsion was carefully examined for
any indication of phase separation or drug precipitation at
time period of 1st hour and followed by at 6th hour [43].
2.2.8. In-vitro drug release study of lovastatin-SMEDDS
In-vitro drug release studies for prepared SMEDDSwere carried
out in 0.1 N HCl and pH 6.8 phosphate buffer solution using
Tablet Dissolution Test Apparatus, Type II (paddle method) at
37 C ± 0.5 C and at paddle speed of 50 rpm. A quantity ofSMEDDS formulations equivalent to 10 mg of lovastatin was
taken into vessels containing 900 ml of dissolution media.
Throughout the release studies, an aliquot of 5-ml was with-
drawn at predetermined time interval, filtered through
membrane filter and analyzed using UV/Spectrophotometer
at 240 nm. Subsequently withdrawn sample was replaced
with equal volume of fresh buffer solution to compensate for
the loss due to sampling and to maintain the sink condition
[25]. The dissolution efficiency at 15th minute (DE15min) for
the formulations and plain drug powderwere also determined
and compared.
2.2.9. Preparation of liquid loadable tablet (LLT)
LLT was prepared by direct compression method and is
comprised of MAMS/Crosspovidone XL 10/magnesium stea-
rate/Talc (88%/10%/1%/1%) in a given proportions. All excipi-
ents passed through sieve 180 mm mesh size to break any
lumps or aggregates, were loaded into lab scale conta blender
(Mec well Pharma Machinery company, Thane, Mumbai,
India) and mixed thoroughly prior to compression. Following
tomixing, blendwas directly compressed using round, 10mm
flat punch tooling. Tablets were evaluated for hardness,
disintegration and dissolution behavior.
2.2.10. Loading of SMEDDS into LLT
Before loading of liquid formulation, compressed LLT were
evaluated for porosity and loading capacity (ml). LLT was
considered fully loaded when the theoretical limit is ach-
ieved which implicates that void spaces are completely
saturated with liquid formulation. In order to load the LLT,
tablet were placed in contact with excess of optimized
lovastatin-SMEDDS formulation and allowed to adsorb the
liquid until a constant weight of tablet is achieved. Prior to
weigh, excess of liquid present over the tablet was wiped off
and dried with a tissue paper. Fully loaded tablets of con-
stant weight were stored in air tight container for further
use.
Tablet porosity: Tablet porosity was determined using
following formula.
ε ¼

1 r
t
rp

 100
where rp and rt represents the pycnometric tablet density and
tablet density respectively.
2.2.11. In-vitro release behavior of loaded LLT
SMEDDS loaded tablets were subjected to in-vitro dissolution
studies in purified water using USP apparatus type 1 (basket
type) set at paddle speed of 50 rpm and temperature of 37 C.
2.2.12. Shelf life determination of the optimized formulations
Accelerated stability studies were carried out to determine the
storage life of developed formulation. The SMEDDS formula-
tion were stored at 30 C, 40 C and 50 C at normal room
humidity conditions for 60 days. Samples were withdrawn
from each temperature condition after predetermined time
period (0, 15, 30, 45 and 60 days) and analyzed for drug content
using the HPLC method [42]. The order of the rate of degra-
dation reaction and the degradation rate constant was
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the below equation:
Slope ¼ K/2.303
The plot of Log K vs. 1/T at various temperatures was
drawn. From the plot K value corresponding to 25 C was
calculated and was used to determine the shelf life of
formulation using following formula [44].
t0.9 ¼ 0.1052/K25
where t0.9 is the time required for 10% degradation of the
drug and is represents the shelf life [45].
2.2.13. Pharmacodynamics effect of lovastatin-SMEDDS and
lovastatin-SMEDDS loaded tablets
Eighteen healthy male New Zealand white rabbits weighing
1.5e2.0 kg were purchased from East Asia Rabbit Corporation
Sdn BhdMalaysia and kept indoors in individual cages Animal
room was maintained under constant environmental condi-
tions (22 C ± 2 C, 40e70% RH) and had alternating 12 h dark
and lightcycle [46].All animalswereacclimatized in theanimal
roomfor twoweeksprior toexperimentsandduring thisperiod
they had free excess to normal Ralston Purina® laboratory
Rabbit chowComplete (PurinaMills,St. LouisMissouri)pelleted
diet and drinkingwater ad libitum. Animal handling and all the
experimental work was done according to protocol and stan-
dard operating procedure (SOPs) approved by international
medical university research and ethical committee. After 2
weeks of acclimatization, Overnight fasted animals were
divided into 6 groups namely G1eG6 (3 Rabbits in one group).
Control group (G1) with normal cholesterol level was main-
tainedon the stock diet of PurinaChow.This feed ismade from
vegetable sources and contains 16% crude protein, 1.5% crude
fat, 17% crude fiber and vitaminA 4650 IU/lb. The remaining 16
rabbits (G2, G3, G4, G5 and G6) were subjected to experimental
treatmentandare fedwith2%contentcholesterol Purina rabbit
chow (Dytes Inc) for 3 weeks in order to induce acute hyper-
cholesterolemia. Group 2 animals were maintained on high
cholesterol dietwhere asGroup3was fedwithhigh cholesterol
diet followed by placebo formulation and served as control i.e.,
with acute hypercholesterolemia but no drug, G4 was admin-
istered with lovastatin suspension (6 mg/kg), G5 was admin-
istered with lovastatin-SMEDDS (6 mg/kg) and finally the G6
was administered with LLT loaded with lovastatin-SMEDDS
(6 mg/kg). The blood was withdrawn from marginal ear vein
of rabbits at weekly interval and serum cholesterol, total
lipid content was determined using in-vitro diagnostic kit
(Cardiochek, San Diego, USA). Determination of serum HDL,
LDL, triglyceride was carried out using Abcam's diagnostic
kit according to themanufacturer's instructions. Abcam's HDL
and LDL/VLDL Cholesterol quantification assay kit offers a
simple method for quantification of above said components
following a proper separation of HDL from LDL and VLDL (very
low density lipoprotein) in serum samples [47]. This is an
enzymatic colorimetric test. In the assay, cholesterol oxidase
distinguishes free cholesterol and develops products which
interact with probe to produce color (570 nm) and fluorescence
(Ex/Em ¼ 538/587 nm). Kit was stored at 20 C.2.2.13.1. High cholesterol diet (HCD). A 2% cholesterol diet was
prepared by adding 2 g of pure cholesterol powder analytical
grade (C75209, Sigma Chemical Co., St. Louis, USA) to each
100 g of grounded rabbit chow pellet (2% cholesterol, w/w, in
food pellet). Before mixing to rabbit chow pellets, cholesterol
powder was dissolved in 40 ml of chloroform in order to
achieve a uniform distribution throughout the feed. After
thorough mixing Chloroform was evaporated by heating the
diet in Hot air oven maintained at 50 C [48,49].
2.2.13.2. Separation of HDL and LDL/VLDL. 100 ml of 2 pre-
cipitation buffer was mixed with 100 ml of serum sample in
microcentrifuge tubes. Mixture was incubated for 10 min at
room temperature, followed by centrifugation at 2000 g. The
separated HDL supernatant was transferred into fresh tubes
and labeled. Precipitates were consists of mixed fraction of
LDL and VLDL. Results of testing were multiplied by time 2 to
compensate the dilution with 2 precipitation buffer solution
[50].
In order to separate the LDL/VLDL precipitate was spun
again at 2000 g, traces of HDL present in supernatant was
removed carefully. LDL/VLDL fraction was suspended in
phosphate buffer pH 7.4 and transferred to fresh tubes and
stored [50].
2.2.13.3. Preparation of standard curve and sample preparation
for colorimetric assay. 20 ml of cholesterol standard provided
with the kit was mixed with 140 ml of cholesterol assay buffer
to produce a stock concentration of 0.25 mg/ml. An aliquot of 0,
4, 8, 12, 16, 20 ml was added into series of 96 well-plates. Vol-
umewas adjusted to 50 ml/well with cholesterol assay buffer in
order to produce 0, 1, 2, 3, 4, 5 mg/well of the cholesterol
standard [50].
2.2.13.4. Preparation of reaction mix. Reaction mix was pre-
pared by mixing cholesterol assay buffer, cholesterol probe,
and enzyme mix and cholesterol esterase [47].
2.2.13.5. Assay. 50 ml of reaction mix was added into well
containing cholesterol standard or test samples, reaction was
incubated for 60 min at 37 C, protected from light. Optical
density was measured at 570 nm in colorimetric microtiter
plate reader [50].3. Results and discussion
One of the main factors to be considered when developing a
self-emulsifying formulation is to escape of any potential drug
precipitation upon its dilution in the gastric fluid [42]. Ideally
SMEDDS formulation is a mixture of oil, surfactants, co-
surfactants with drug and it should produce a transparent
clear single phase liquid at normal conditions when mixed
with aqueous phase [43] and should have good solubilizing
capacity for drug under study. In order to have the drug in
solution form [51], it is assumed that the ingredients used in
the SMEDDS could enhance the solubility and permeability of
drug by considerably reducing the droplet size [52]. Determi-
nation of oil with the highest solubilization capacity for the
Fig. 1 e Pseudo-ternary phase diagram of formulations made up of peceol, cremophor/transcutol-P (S/CoS 1:1) indicating the
microemulsion area: (A) 45.08 cm2, (B) 45.96 cm2 (C) 46.20 cm2
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Fig. 2 e Pseudo-ternary phase diagram of formulations made up of peceol, cremophor/transcutol-P (S/CoS 2:1) indicating the
microemulsion area: (A) 42.36 cm2 (B) 44.04 cm2 and (C) 43.08 cm2
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Fig. 3 e Pseudo-ternary phase diagram of formulations made up of peceol, cremophor/transcutol-P (S/CoS; 3:1) indicating
the microemulsion area (Me): (A) 44.00 cm2 (B) 42.48 cm2 (C) Me ¼ 43.20 cm2
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Table 2 e Mean area of microemulsion region at three
different ratio of surfactant to co-surfactant ratio (S/CoS).
Ratio Area of microemulsion region (cm2)
1 2 3 Mean
1:1 45.08 45.96 46.20 45.75
2:1 42.36 44.04 43.08 43.16
3:1 44.00 42.48 43.20 44.04
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emulsion formed upon dilution to retain the drug in solubi-
lized form is largely dependent on its solubility in the oil phase
of the system. If the surfactant and co-surfactant contribute to
a great extent for the solubilization of the drug, there possess
a risk of drug precipitation upon dilution with aqueous phase.
In addition, the surfactant selected should be capable of
lowering the surface tension to a very low level to aid the
dispersion process. Generally, non-ionic surfactants with high
HLB values are used in SMEDDS formulation, as it had been
reported that surfactants with HLB value between 12 and 15
are considered to possess good efficiency for self-emulsifica-
tion [24]. Apart from that, the incorporation of co-surfactants
along with surfactant to the system also enables the dissolu-
tion of significantly large amount of either the drug or hy-
drophilic surfactants in the hydrophobic (oil) phase [4].
Organic solvent like polyethylene glycol (PEG), propylene
glycol (PG) and transcutol-P are particularly useful as co-
surfactant in formulating SMEDDS, since they are suitable
for oral delivery.
3.1. Solubility study
The solubility of lovastatin in the different oils, surfactants
and co-surfactants is presented in Table 1. The results of one-
way ANOVA showed that there are statistically significant
differences among the solubility of different oils, since the
p-value (labeled “sig”) is less than 0.05. Peceol has shown the
highest solubility among the oils. The results obtained of
Post-Hoc Tukey test clearly revealed that there are statisti-
cally significant differences between peceol and labrafac lip-
ophile, labrafac PG. Llbrafil M1944 as well as Olive Oil, with a
p-value <0.05. Among all the surfactants and co-surfactant
studied, cremophor and transcutol-P showed the highest
solubility for lovastatin (24.66 mg/ml and 37.54 mg/ml
respectively). A statistically significant difference was found
among the solubility of different surfactant and co-
surfactants (p-value < 0.05). The results of Tukey Post-hoc
test clearly indicates that there are statistically significant
difference between cremophor and all the other surfactants
(p-value < 0.05), except labrasol (p-value ¼ 0.062; >0.05) and
Tween 40 (p-value ¼ 0.2262; >0.05) as well as transcutol-P and
with all other co-surfactants, including PEG 300, PEG 400 and
PEG 600 (p-value < 0.05). As per the results obtained after
solubility studies, peceol, cremophor and transcutol were
chosen as oil, surfactant and co-surfactant respectively for
the proposed SMEDDS formulation.
3.2. Construction of pseudo-ternary phase diagram
The purpose of constructing pseudo-ternary phase diagram is
to determine the microemulsion area for the selection of
appropriate concentrationsof oil, surfactant and co-surfactant
in subsequent SMEDDS formulation development. There are
few factors which determine the range of microemulsion re-
gion formed during the water-titration, including the physical
and chemical properties of the oil phase, aqueous phase and
surfactants used [53,54] as well as the necessary conditions
needed for microemulsion formation. To be precise, these
required conditions would include a less interfacial tension atthe hydrophilic and hydrophobic interface, the presence of
highly fluid and flexible interfacial film as well as the pene-
tration and association of oil molecules with the interfacial
surfactant film [53,54]. Hydrophilicelipophilic balance (HLB)
value of surfactant and co-surfactant used in formulation is a
key factor for the development of self-emulsion. Surfactants
having HLB in the range of 12e15 are generally considered to
have good efficiency for self-emulsification [53,55].
Phase diagramwere constructed at three different ratios of
surfactant to co-surfactant (1:1, 2:1 and 3:1) as shown in Figs.
1e3. Experiment was repeated in triplicate as presented by A,
B and C for each ratio. Among all three ratios, it is evident that
the surfactant to co-surfactant ratio of 1:1 produced a
comparatively largest microemulsion region than the other
two ratios as shown in Fig. 1AeC. Results are also summarized
in Table 2. The one-way ANOVA suggests that there are sta-
tistically significant differences among the mean micro-
emulsion area at different ratio of surfactant:co-surfactant
(1:1, 2:1, 3:1), as the p-value is less than 0.05 (p-value ¼ 0.008).
Since the phase diagram of the ratio 1:1 yielded the greatest
area of microemulsion region, the procedure of water-titra-
tion was repeated in triplicate in the presence of lovastatin for
the same ratio to explore the effect of drug addition on the
boundaries of microemulsion region as shown in Fig. 4AeC.
A decrease in the area of the microemulsion region was
observed following incorporation of 10 mg lovastatin. The
mean microemulsion area of the phase diagrams con-
structed with lovastatin added was calculated to be
39.57 cm2, which is smaller than the phase diagram con-
structed without lovastatin added at the same ratio (1:1). A
decrease in the microemulsion area is attributed to the
incorporation of the drug into the oil droplets (lipid phase)
resulting in the swelling of the oil droplets or expansion of
lipid phase. Hence, an increase in the droplet size of the
emulsion formed leads to a decrease in the clear region
(microemulsion area) in the pseudo-ternary phase diagram
which in turn leads to a need for a higher S/CoS ratio for
emulsion stability [43].
The results of paired sample T-test suggest that there is a
statistically significant difference between the mean micro-
emulsion area of the phase diagram at ratio 1:1 constructed
with and without lovastatin added.3.3. Formulation of self-emulsifying microemulsion
A total of eight combinations were selected from the
microemulsion region of the pseudo-ternary phase diagram
constructed with added lovastatin. The percentages of
peceol, cremophor and transcutol-P in each formulation
were illustrated in Table 3. All the selected eight SMEDDS
Fig. 4 e Pseudo-ternary phase diagram of formulations made up of peceol, cremophor/transcutol-P (S/CoS; 1:1 together with
lovastatin, indicating the microemulsion area (Me). (A) 39.52 cm2(B) 39.16 cm2 (C) 40.04 cm2.
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Table 3 e Selected formulations from the microemulsion
region of the pseudo-ternary phase diagram constructed
with lovastatin.
Component (% w/w) Formulation code
A B C D E F G H
Lovastatin (mg) 10 10 10 10 10 10 10 10
Peceol 60 40 34 25 15 12 20 18
S/CoS ratio 1:1 1:1 1:1 1:1 1:1 1:1 1:1 1:1
Cremophor RH 40 20 30 33 37.5 42.5 44 40 41
Transcutol P 20 30 33 37.5 42.5 44 40 41
Table 5 e Droplet size analysis for selected four SMEDDS
formulations.
Formulations Droplet size (nm)
1 2 3 Mean ± SD
E 103.0 101.7 103.3 102.7 ± 0.850
F 74.4 71.1 71.1 72.2 ± 0.133
G 239.9 241.8 238.8 240.2 ± 1.518
H 177.5 179.7 180.4 179.2 ± 1.553
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 4 0e5 650formulations passed the thermodynamic stability tests, as
none of them showed any signs of drug crystallization,
phase separation, cracking, creaming or any other signifi-
cant changes in physical appearance after subjected to the
freezeethaw cycle and centrifugation test. All formulations
which survived thermodynamic stability tests were sub-
jected to further evaluation, including dispersibility studies,
droplet size and zeta potential analysis as well as in-vitro
dissolution test.3.4. Precipitation and dispersibility analysis
Out of eight formulations, formulations B and C were precip-
itated on dilution with 0.1 N HCl at 250 times after 6 h.
Although there was no sign of precipitation up to 2 h in all
formulations. The capability of the self-emulsification of the
developed SMEDDS formulations was evaluated by dis-
persibility studies. Distilled water was chosen to be used as
the medium to disperse the formulation since it is believed
that there is no significant difference if the formulations
prepared with non-ionic surfactants, is dispersed in either
water or simulated biological fluids [56,57],. The results of the
dispersibility test for the eight different SMEDDS formulations
are summarized in Table 4.
Formulations which fell under grade C or milky appear-
ance in dispersibility test (formulation A, B, C and D) were
rejected. The remaining formulations of grade A and B (clear
to bluish in appearance) namely formulation E, F, G and H
were subjected to the subsequent evaluations.Table 4 e Results of dispersibility test for selected eight differe
Observation
Formulation Appearance Emulsification time (s
1 2 3
A Milky 80 75 80
B Milky 70 70 75
C Milky 65 60 70
D Milky 65 75 75
E Clear 30 25 30
F Clear 35 30 25
G Bluish 45 40 50
H Bluish 40 40 35
*Assessment of self microemulsion efficiency.
a Grade A: Instantly forming microemulsion, with very clear or bluish ap
b Grade B: Instantly forming but slightly less/almost clear microemulsio
c Grade C: Milky white microemulsion formed within 2e3 min.3.5. Droplet size analysis
Formulation F which contains 12% of oil phase (Peceol) shown
the smallest mean droplet size of <75 nm (Table 5). It was
observed that as the percentage of oil phase in the formula-
tions increases from 15% to 20% and the percentage of sur-
factant mixture decreases simultaneously from 85% to 80%
there is a proportional increase in themean droplet size of the
formulations. This is consistent with the research studies
which states that surfactants added into the microemulsion
systems is mainly helps in stabilization and condensation of
the interfacial film which in further improves the thermody-
namic stability of produced system. Presence of co-surfactant
results in expansion of interfacial film [58]. Hence, higher ratio
of surfactant to co-surfactant mixture would produce smaller
droplets by decreasing the interfacial tension and conse-
quently enabling a closely packed system [59].
Globule size is one of the most critical criteria to be eval-
uated in the SMEDDS formulation development. It is the key
factor which affects the rate and extent of drug release [38] as
well as in-vivo drug absorption in the intestine. It is reported
that emulsion with smaller droplet size leads to more rapid
intestinal drug absorption henceforth improves the bioavail-
ability of the poorly absorbed drug [60]. Formulation F is
considered as optimized formulation.
3.6. Zeta potential analysis
The zeta potential of formulations is measured by Malvern
Zetasizer. The stability of the emulsions formed is directly
related to the magnitude of the zeta potential, or surfacent SMEDDS formulations.
Precipitation analysis
econds) Gradea,b,c After 2 h After 6 h
Mean
78.3 C Clear Cloudy
71.7 C Clear Cloudy
65.0 C Clear Clear
71.7 C Clear Clear
28.3 A Clear Clear
30.0 A Clear Clear
45.0 B Clear Clear
38.3 B Clear Clear
pearance.
n, with bluish white appearance.
Table 6 e Results of zeta potential analysis for selected
four SMEDDS formulations.
Formulations Zeta potential (mV)
1 2 3 Mean ± SD
E 11.32 11.60 10.48 11.13 ± 0.582
F 12.56 12.64 11.16 12.12 ± 0.832
G 11.06 11.72 14.89 12.55 ± 2.047
H 10.79 12.76 13.52 12.39 ± 1.353
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existing between the droplet surface and the dispersing liquid
that will vary accordinglywith the distance of the ion from the
droplet surface [61]. Large zeta potential of the droplets would
create electrostatic repulsive forces among the droplets, thus
giving the system dispersion stability to prevent coalescence
of the droplets. In contrast, lower zeta potential would
decrease the repulsive forces among the droplets, resulting in
phase separation. It has been reported that a dividing line
between stable and unstable aqueous dispersions is generally
taken at either þ30 or 30 mV, which means particles with
zeta potentials greater than þ30 mV or smaller than 30 mV
could be considered stable [15,62]. However, in the present
study, the zeta potential of the four formulations (E, F, G and
H) evaluated ranged between10.48 to14.89mv as shown in
Table 6.3.7. In-vitro dissolution studies for developed SMEDDS
Results of release studies are presented in Fig. 5 for formula-
tion F in 0.1 NHCL and phosphate buffer pH 6.8. It can be seen
clearly that lovastatin which is a lipophilic drug released at
significantly faster rate from SMEDDS formulations compared
to pure drug. It could be suggested that SMEDDS formulation
formsmicroemulsion with a small droplet size spontaneously
upon its introduction into the dissolution media (pH 6.8
phosphate buffer and 0.1 NHCl) that permits faster rate of drug
release into the aqueous phase, if compared to the pure
lovastatin. The mean dissolution efficiency (DE15min) for
formulations F and pure drug was calculated to 0.9216, 0.1602
in phosphate buffer pH 6.8 and 0.8143, 0.0787 in 0.1 N HCl
respectively. The statistical test performed on the dissolutionFig. 5 e In-vitro dissolution profile of optimized SMEDDS
formulation F and pure drug in pH 6.8 phosphate buffer
and 0.1 N HCL.efficiency (DE15min) suggests that there is statistically sig-
nificant difference between the dissolution rate of SMEDDS
formulations, and pure lovastatin. Hence, this greater avail-
ability of dissolved form of lovastatin from the SMEDDS
formulations could ultimately lead to higher intestinal
absorption and thus higher oral bioavailability [38].
3.8. Preparation of LLT
Neusilin US2 is a spray dried very fine and ultra-light spherical
granules of magnesium aluminometasilicate having high
liquid absorbing capacity due to its large surface area and
porous nature [35]. LLT of approximately 250 mg were pre-
pared by direct compression of Neusilin US2 with 10% cro-
spovidone XL 10 to facilitate the disintegration and fast
release of medicament. Prepared tablets have shown the
porosity of 76%. Pycnometric density was determined using
Accupyc 1330 Micromeritics instrument and found to be
1.87 g/cm3. Tablet density was also determined from tablet
weight and volume. Tablets porositywas found to be inversely
proportional to the compression force applied. Tablets com-
pressed with less force exhibited high porosity with sufficient
hardness required for further processing. Since tablet has to
adsorb a significant quantity of liquid afterward, a hardness of
6e7 kg were considered to be suitable for LLT tablets in order
to have a sufficiently hard loaded tablet finally.
3.9. Loading of SMEDDS in Neusilin® US2 tablets.
Amount of oil or liquid absorbed by LLT is depends on the
porosity of prepared tablets, tablet with high porosity takes a
large amount of oil/liquid. In this study LLT has found to
absorb around 76% of lovastatin-SMEDDS. After loading the
liquid, loaded tablets have shown a very low weight variation,
which strongly suggests the uniform loading in tablets.
However, there was slight decrease in hardness of tablet
attributed to adsorption of liquid. SMEDDS loaded LLT have
shown a hardness of around 4e5 kg.
3.10. Liquid loading capacity of prepared LLT in
comparison of soft capsule
As per the manufacturer's specification of Neusilin® US2,
magnesium aluminometasilicate can absorb approximatelyFig. 6 e In-vitro drug release profile of SMEDDS loaded LLT
and SMEDDS containing lovastatin.
Fig. 7 e Accelerated stability studies for the optimized
formulation F.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 4 0e5 6523 ml/g of liquid theoretically. It is reported that, after
compression, tablets having porosity between 64 and 81% can
absorb around 0.92e2.21 ml/g of liquid or oil [63]. On the other
hand, soft capsule has less loading volume because of thick
shell. As per the information revealed by SGcaps® Capsugel,
around 33% of volume is occupied by thick capsule shell. Hard
gelatin capsule have thin wall therefore a large volume of
liquid can be filled into these capsules but in order to avoid the
risk of spillage during handling of capsules only 85e90% of
total volume is filled with some unfilled space. As per theTable 7 e Effects of high cholesterol diet on rabbits lipid profil
Group Parameter Avg. 
Normal 
values 
High cholesterol 
diet
A
fter 4  w
eek T
reatm
ent 
1 Cholesterol mg/dl
LDL (mg/dl)
HDL (mg/dl)
Triglyceride(mg/dl)
39.41±11.3
19.65±5.2
36.76±3.4
46.54±6.5
NA
2 Cholesterol mg/dl
LDL (mg/dl)
HDL (mg/dl)
Triglyceride(mg/dl
41.34±6.56
22.61±7.22
38.63±5.21
48.54±7.66
1687.54± 104.3
497.76±52.78
27.76± 4.2
75.67±2.5
3 Cholesterol mg/dl
LDL (mg/dl)
HDL (mg/dl)
Triglyceride(mg/dl
41.67±6.56
17.55±2.16
47.65±4.33
51.34±2.91
1532.44±6.56
521.65±21.87
24.88±2.93
73.42±6.56
1
5
2
7
4 Cholesterol mg/dl
LDL (mg/dl)
HDL (mg/dl)
Triglyceride(mg/dl
47.62±8.76
37.76±3.21
21.32±6.33
43.54±11.5
1578.87± 94.37
598.88±51.31
57.61±5.28
73.66±2.2
5 Cholesterol mg/dl
LDL (mg/dl)
HDL (mg/dl)
Triglyceride(mg/dl
51.32±8.21
39.54±4.51
17.43±6.67
48.88±9.11
1722.87±113.5
651.24±39.88
53.77± 4.32
77.02± 2.10
6 Cholesterol mg/dl
LDL (mg/dl)
HDL (mg/dl)
Triglyceride(mg/dl
48.54±11.2
34.65±4.7
25.23±7.7
53.47±8.4
1712.65±75.77
632.97± 48.61
64.78± 6.55
68.75± 6.9manufacturer's specification for hard gelatin capsule, only
72e77% volume of a capsule can be utilized for liquid filling
(Posilok®, Qualicaps Inc.). At the same time, LLT can fill up to
80% of the total available volume depending on the porosity of
tablet. After loading LLT can be thin coated to protect the
loaded formulation.
3.11. In-vitro dissolution studies for developed solid
SMEDDS
In-vitro dissolution test was carried out in purified water as
dissolution medium using USP apparatus-1 (basket). Dissolu-
tion behavior of LLT was compared with capsule loaded with
lovastatin suspension and capsule filled with lovastatin-
SMEDDS. Capsule filled with lovastatin-SMEDDS rapidly dis-
integrated and released its content immediately. Lovastatin
suspension has shown a very less dissolution as expected. LLT
loaded with SMEDDS have shown a slower release profile
compared to capsule filled with lovastatin-SMEDDS. After 1 h
of dissolution approx. 85% of total drug was released from LLT
whereas with capsule filled with lovastatin-SMEDDS almost
98% drug was found to be released. Results are illustrated in
Fig. 6. After introducing loaded LLT into aqueous dissolution
medium, loaded liquid is released into environment. Because
of amphiphilic nature of SMEDDS, released liquid is easily and
completely mixed with the aqueous medium. In-vitro study
showed that tablets were dispersed immediately releasing
formulation into dissolution media, which forms an emulsion
with an average globule size of 78 ± 5.45 nm. The globule sizee followed by treatment with lovastatin formulations.
Placebo 
SMEDDS
Lovastatin 
suspension
-Lovastatin
SMEDDS
Lovastatin -
SMEDDS loaded 
LLT
NA
NA
632.44±7.56
14.65±11.87
2.88±4.93
3.42±7.56
1427±74.77
487± 32.54
62.78±2.76
58.76±5.33
NA NA
NA
462.44±24.7
175.61±33.19
75.77± 5.11
39.77±2.72
NA
NA NA
471.87±31.77
173.21±14.22
72.66±4.71
37.78±3.10
Fig. 8 e Results of pharmacodynamics study conducted on diet induced hyperlipidemic rabbits. (A) effect on cholesterol
profile, (B) effect on LDL profile (C) effect on HDL profile (D) effect on triglyceride profile of group G1: normal animals, G2:
animals administered placebo SMEDDS with no drug, G3: animals administered high cholesterol diet (HCD), G4: animals
given HCD and lovastatin suspension, G5: animals administered with HCD and lovastatin-SMEDDS, and G6: animals given
HCD and lovastatin-SMEDDS loaded liquid loadable tablets.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 4 0e5 6 53of microemulsion from LLT SMEDDS is slightly larger than the
droplet size produced by liquid SMEDDS. This shows that
procedure involved in making of SMEDDS-LLT does not affect
the morphology of droplets of SMEDDS. Release of content
from loaded LLT could be explained with convective and
diffusive mechanism. Presence of crosspovidone XL 10 in
tablet formula facilitates the release of drug by reducing the
diffusional path length.3.12. Shelf life determination
In order to determine the shelf life of developed optimized
formulation, Accelerated stability studies were carried out at
different temperature conditions (30, 40 and 50 C). At the end
of 60 days, concentration of drug remaining undecomposed
was determined and found to be 97.12%, 95.16% and 85.22% at
30 C, 40 C and 50 C respectively as shown in Fig. 7. Formu-
lation were also observed for any physical change and insta-
bility and found to be stable at above stability conditions. The
shelf life of the developed SMEDDS at room temperature was
found to be 1.92 years.3.13. Pharmacodynamics study
Formulation (F) optimized after in-vitro screening, was sub-
jected for pharmacodynamics evaluation in rabbit as an
animal model. The standard curve for the enzymatic deter-
mination of cholesterol, and triglyceride were prepared
according to the instruction given in kit protocol. Hypercho-
lesterolemia was induced by feeding high cholesterol diet to
the rabbits. Subsequent to 4 week feeding of 2% high choles-
terol diet, total cholesterol was significantly increased to
1579e1723 mg/dl from 48.2 mg/dl of average normal value.
SimilarlyLDLalsoelevated to498.5e653.8g/dl from38.54mg/dl
innormal rabbits. During 4week feedingof 2%high cholesterol
diet, bloodcholesterol levelwasmaintainedelevated.Once the
appropriate elevation in lipid profile was achieved, animals
were divided into 6 groups as shown in Table 7, group 1 was
maintained at normal diet, group 2 was maintained on high
cholesterol diet whereas group 3 was maintained on placebo
SMEDDSwithout drug but on high cholesterol diet. Remaining
groups fed with high cholesterol diet were treated with lova-
statin suspension, lovastatin-SMEDDS and lovastatin-
SMEDDS loaded LLT respectively. From the results obtained
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 4 0e5 654of pharmacodynamics study, it was noted that lovastatin
suspension has reduced the cholesterol level
(1578.87 ± 94.37 mg/dl to 1427 ± 74.77 mg/dl), triglyceride level
(73.66± 2.2 to 58.76± 5.33) andLDL level (598.88± 51.31mg/dl to
487 ± 32.54 mg/dl) as shown in Fig. 8A, B and D respectively. A
slight increase in HDL level was also recorded with lovastatin
suspension (Fig. 8C), whereas rabbit treated with lovastatin-
SMEDDS and lovastatin-SMEDDS loaded LLT have shown a
significant drop in their elevated lipid profile. After a treatment
period of 4 weeks lovastatin-SMEDDS has shown to lowered
down the cholesterol level from 1722.87 ± 113.5 mg/dl to
462.44 ± 24.7 mg/dl, LDL from 651.24 ± 39.88 mg/dl to
175.61 ± 33.19 mg/dl (Table 7). Similarly, lovastatin-SMEDDS
loaded tablet also have shown the comparable results and a
significant increase in HDL level too. All the results are illus-
trated in Fig. 8AeD. The antihyperlipidemic activity of
lovastatin-SMEDDS and LLTwere substantially higher (p < 0.5)
compared to lovastatin suspensionwhich indicates the higher
bioavailability orhigherplasmaconcentrationof administered
lovastatin achieved by these formulation. This improved ac-
tivity of lovastatin can be explicated by the virtue of SMEDDS
capability to present the drug in solubilized form which
contemporarily increases the absorption of drug and thereby
lead to increase plasma concentration. Poor bioavailability of
lovastatin is due to its very low aqueous solubility which re-
sults in poor absorption and therapeutic activity which has
beenclearly seenwith lovastatin suspension. Thedifference in
pharmacodynamics activity of lovastatin suspension and
SMEDDS and in-vitro dissolution studies have advocated that
SMEDDS formulation is capable of presenting poorly soluble
drug in solubilized formwhichmay improve thebioavailability
and therapeutic activity as well for such drug molecules.
SMEDDS loaded into LLT also have shown the equivalent
pharmacodynamics activity which suggests that LLT could be
an appropriate and successful housing for administering
SMEDDS. In this study LLT was found to absorb around 1.8 ml/
gm of liquid SMEDDS. A high loading efficiency is always
desired in order to formulate a small solid dosage form with
high liquid content. Attributed to high liquid loading capability
of these tablets, this technology is therefore recommended as
better option compared to other possible substitute like,
capsule filled SMEDDS, powder absorbed SMEDDS, liquid
loaded beads etc. From commercial point of view also, this
technology is easier to scale up since simple conventional
method of tablet manufacturing is involved in making these
liquid loaded tablets. Liquid is loaded into tablet by simple
dipping method. Liquid is entrapped into tablet by capillary
actionwhich prevents the leaking of liquid [63]. LLTwas found
to be a successful, effective and potential alternative with a
high porosity and loading capability compared to other
commonlyusedcarriers forSMEDDS.LLTalsohelps to improve
the physical and chemical stability of the liquid formulation as
it is trapped inside the solid matrix [63].4. Conclusion
In this present study, self-emulsifying microemulsion was
developed for lovastatin. Optimized SMEDDS formulation
comprises of 12% peceol, 44% cremophor RH 40 and 44%transcutol-P, which showed spontaneous emulsification
properties and good thermodynamic stability. SMEDDS
formulation showed a better in-vitro release profile compared
with pure drug. As per the stability studies, formulation was
found to be fairly stable with expected shelf life of 1.92 years.
Form pharmacodynamics studies it could be concluded that
SMEDDS formulation for lovastatin has shown a significantly
higher lipid lowering activity compared to lovastatin suspen-
sion. At the same time, Neusilin® US2 liquid loadable tablets
was also seen to be potential carrier with high loading ca-
pacity for administering liquid SMEDDS and an alternative to
hard and soft gelatin capsules.
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